Boron-containing small molecules as anti-inflammatory agents
Compounds and methods of treating anti-inflammatory conditions are disclosed.
1. A compound having a structure according to the formula:
wherein
R a is C(O)OR 3
wherein R 3 is unsubstituted alkyl,
X is N or CH,
R b is OR 4
wherein R 4 is unsubstituted straight chain or branched chain alkyl, or straight chain or branched alkyl substituted with unsubstituted cycloalkyl, or unsubstituted cycloalkyl,
or a salt thereof.
2. The compound of claim 1 , or a salt thereof, wherein the compound has a formula which is a member selected from:
3. The compound of claim 1 , or a salt thereof, wherein the compound has a formula which is a member selected from:
4. The compound of claim 1 , or a salt thereof, wherein the compound has a formula which is a member selected from:
5. The compound of claim 4 , or a salt thereof, wherein the compound is
6. The compound of claim 1 , or a salt thereof, wherein the compound has a formula which is a member selected from:
7. The compound of claim 6 , or a salt thereof, wherein R 3 is methyl or C 2 alkyl or C 3 alkyl.
8. The compound of claim 6 , or a salt thereof, wherein R 3 is C 4 alkyl or C 5 alkyl or C 6 alkyl.
9. The compound of claim 7 , or a salt thereof, wherein R b is OR 4 , and R 4 is unsubstituted C 1 -C 6 straight chain or branched chain alkyl.
10. The compound of claim 9 , or a salt thereof, wherein R 4 is unsubstituted C 1 or C 2 or C 3 straight chain or branched chain alkyl.
11. The compound of claim 9 , or a salt thereof, wherein the compound is
12. The compound of claim 9 , or a salt thereof, wherein the compound is
13. The compound of claim 9 , or a salt thereof, wherein the compound is
14. The compound of claim 9 , or a salt thereof, wherein the compound is
15. The compound of claim 1 , or a salt thereof, wherein the compound is
16. The compound of claim 1 , or a salt thereof, wherein the compound is
17. The compound of claim 16 , or a salt thereof, wherein the salt is a pharmaceutically acceptable salt.
18. The compound of claim 9 , or a salt thereof, wherein R 4 is unsubstituted C 4 or C 5 or C 6 alkyl.
19. The compound of claim 9 , or a salt thereof, wherein R 4 is methyl or ethyl or propyl or isopropyl or isobutyl.
20. The compound of claim 1 , or a salt thereof, wherein R b is OR 4 , and R 4 is straight chain or branched chain alkyl substituted with unsubstituted cycloalkyl.
21. The compound of claim 1 , or a salt thereof, wherein R b is OR 4 , and R 4 is
22. The compound of claim 1 , or a salt thereof, wherein the compound is
23. The compound of claim 1 , or a salt thereof, wherein R b is OR 4 , and R 4 is unsubstituted cycloalkyl.
24. The compound of claim 1 , or a salt thereof, wherein R b is OR 4 , and R 4 is cyclopentyl or cyclohexyl.
25. The compound of claim 1 , or a salt thereof, wherein the compound is
26. A pharmaceutical formulation comprising:
(a) the compound of claim 1 , or a pharmaceutically acceptable salt thereof; and
(b) a pharmaceutically acceptable excipient.
27. The formulation of claim 26 , wherein the compound is
28. The formulation of claim 26 , which is a topical formulation.
29. The formulation of claim 26 , wherein the formulation is a lotion or cream or foam or gel or ointment.
30. A method of treating a condition in an animal in need of the treatment, the method comprising administering to the animal a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof, thereby treating the condition, wherein said condition is psoriasis or dermatitis.
31. The method of claim 30 , wherein the compound is
32. The method of claim 31 , wherein the condition is psoriasis.
33. The method of claim 31 , wherein the condition is psoriasis, and said psoriasis is plaque psoriasis.
34. The method of claim 31 , wherein the condition is psoriasis, and said psoriasis is flexural psoriasis.
35. The method of claim 31 , wherein the condition is psoriasis, and said psoriasis is guttate psoriasis.
36. The method of claim 31 , wherein the condition is psoriasis, and said psoriasis is pustular psoriasis.
37. The method of claim 31 , wherein the condition is psoriasis, and said psoriasis is nail psoriasis.
38. The method of claim 31 , wherein the condition is psoriasis, and said psoriasis is psoriatic arthritis.
39. The method of claim 31 , wherein the condition is psoriasis, and said psoriasis is erythrodermic psoriasis.
40. The method of claim 31 , wherein the condition is dermatitis.
41. The method of claim 31 , wherein the condition is dermatitis, and said dermatitis is contact dermatitis.
42. The method of claim 31 , wherein the condition is dermatitis, and said dermatitis is atopic dermatitis.
43. The method of claim 31 , wherein the condition is dermatitis, and said dermatitis is eczema.